Full year net sales were $19.1 billion.
That's up 4% year-on-year and included a 2 point drag from currency rates.
Organic sales grew 6%, with healthy underlying performance and increased demand related to COVID-19.
Volumes were up 4%, and net selling prices and product mix each increased 1%.
Full year adjusted gross margin was 37.1%, up 210 basis points year-on-year.
Adjusted gross profit increased 10%.
We generated $575 million of cost savings from our FORCE and restructuring programs.
For 2021, we're targeting $400 million to $460 million in total cost savings.
Commodities were favorable by $175 million in 2020 although they turned inflationary in the fourth quarter.
We're planning for commodity inflation of $450 million to $600 million in 2021.
Moving further down the P&L, between the line spending was up 110 basis points as a percent of sales.
That was driven by advertising, which was up 90 basis points.
Adjusted operating margin was 18.7%, up 90 basis points, and adjusted operating profit grew 9%.
In terms of Company profitability for 2021, the midpoint of our planning assumptions implies a 70 basis point decline in adjusted operating margin.
Full year adjusted earnings per share were $7.74, up 12%.
Our October guidance was for earnings of $7.50 to $7.65.
Now let's turn to cash flow [Technical Issues] Cash provided by operations was an all-time record $3.7 billion, up $1 billion year-on-year, reflecting outstanding working capital performance and strong earnings.
Capital spending was $1.2 billion in 2020, in line with plan and the prior year.
We plan to spend between $1.2 billion and $1.3 billion in 2021, including activity for our restructuring program and a pickup in growth projects.
On capital allocation, dividends and share repurchases totaled $2.15 billion.
That's the 10th consecutive year we've returned at least $2 billion to shareholders.
We're about 85% to 90% through the total pre-tax charges, which we've increased somewhat to reflect delays as a result of COVID-19 and costs for additional savings opportunities.
So far, we've generated $420 million of savings and expect to achieve between $540 million and $560 million of savings by the end of 2021.
Our original savings estimate was $500 million to $550 million.
Finally, at this point cash payments are about 75% to 80% complete.
Looking more closely at our business segments, we saw excellent performance in Personal Care, with 5% organic sales growth and strong share performance.
In North America, organic sales rose 6%, driven by broad-based growth in baby and child care.
In D&E markets, personal care organic sales were also up 6% despite volatile market conditions.
Organic sales were up 13% in Consumer Tissue and down 7% in K-C Professional.
Importantly, we grew or maintained market share in approximately 60% of the 80 key cohorts that we track.
Our plans call for total sales growth of 4% to 6% in 2021, and that includes 2 points from the Softex acquisition and a 1 to 2 point benefit from currencies.
We expect to grow organic sales 1% to 2%.
On the bottom line, we're targeting adjusted earnings per share of $7.75 to $8.
That's even to up 3% year-on-year.
So on that basis, using the midpoint of our 2021 outlook, we're projecting to grow organic sales approximately 4% and to increase adjusted earnings per share 7% on average over that two-year period.

Summary:
Looking more closely at our business segments, we saw excellent performance in Personal Care, with 5% organic sales growth and strong share performance.
Our plans call for total sales growth of 4% to 6% in 2021, and that includes 2 points from the Softex acquisition and a 1 to 2 point benefit from currencies.
On the bottom line, we're targeting adjusted earnings per share of $7.75 to $8.